Lung cancer is a leading cause of cancer‐related deaths worldwide,[33] with a significant portion attributed to non‐small cell lung cancer (NSCLC).[38] Many NSCLC cases exhibit alterations in the human epidermal growth factor receptor (EGFR) gene, which EGFR inhibitors can target.[39] Precise determination of EGFR variant allele frequency (VAF) is vital for predicting treatment response and determining the metastatic stage of the disease.[40] While NGS and qPCR are commonly used for this purpose, they face limitations in sensitivity and cost. This evidence concerns the gene EGFR and non-small cell lung carcinoma.